Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

18.68
+0.08000.43%
Pre-market: 18.880.2000+1.07%04:35 EDT
Volume:1.07M
Turnover:20.19M
Market Cap:1.14B
PE:-11.37
High:19.14
Open:18.72
Low:18.55
Close:18.60
52wk High:35.34
52wk Low:12.12
Shares:61.14M
Float Shares:49.82M
Volume Ratio:1.17
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6429
EPS(LYR):-1.8336
ROE:-10.70%
ROA:-8.80%
PB:1.23
PE(LYR):-10.19

Loading ...

Janux nominates development candidate in Bristol Myers Squibb deal, triggers $35 million milestone

Reuters
·
Apr 01

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

THOMSON REUTERS
·
Apr 01

Janux Therapeutics Inc - Eligible for Additional Milestone Payments and Tiered Royalties on Global Sales

THOMSON REUTERS
·
Apr 01

Janux Therapeutics Inc - to Support Bristol Myers Squibb Through First Phase 1 Clinical Study

THOMSON REUTERS
·
Apr 01

Janux Therapeutics price target lowered to $80 from $100 at Truist

TIPRANKS
·
Mar 03

Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating

MT Newswires Live
·
Mar 03

Janux Therapeutics Inc : Truist Securities Cuts Target Price to $80 From $100

THOMSON REUTERS
·
Mar 03

Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating

TIPRANKS
·
Mar 02

Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating

TIPRANKS
·
Feb 28

Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald

TIPRANKS
·
Feb 27

Janux Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 27

Piper Sandler Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Feb 27

Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities

TIPRANKS
·
Feb 27

Janux Therapeutics price target lowered to $68 from $72 at Guggenheim

TIPRANKS
·
Feb 27

Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform

TIPRANKS
·
Feb 27

Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Benzinga Earnings
·
Feb 27

Janux Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Janux Therapeutics Q4 net loss widens on higher R&D expenses

Reuters
·
Feb 27

BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51

Reuters
·
Feb 27

Janux Therapeutics Q4 Net Income USD -42.401 Million

THOMSON REUTERS
·
Feb 27